Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis

Similar documents
Prognostic significance of epidermal growth factor receptor (EGFR) over expression in urothelial carcinoma of urinary bladder

Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer

Prognostic utility of epidermal growth factor receptor (EGFR) expression in prostatic acinar adenocarcinoma

Role of peritoneal washing cytology in ovarian malignancies: correlation with histopathological parameters

Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma

Surgical and Experimental Pathology

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

Urinary Bladder, Ureter, and Renal Pelvis

Bone Metastases in Muscle-Invasive Bladder Cancer

Immunohistochemical determinations in evaluating the prognostic in patient with urinary bladder tumors

American Journals of Cancer Case Reports. A Rare Case of Rectal Metastasis from Sarcomatoid Variant of Urothelial Carcinoma: A Case Report

Carcinoma of the Urinary Bladder Histopathology

ACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI

Urothelial Carcinoma With Squamous Differentiation Is Associated With High Tumor Stage and Pelvic Lymph-Node Metastasis

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

Original Article Squamous cell carcinoma in a duplicated renal pelvis

BLADDER CANCER EPIDEMIOLOGY

A patient with recurrent bladder cancer presents with the following history:

Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature


Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer

The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder

A215- Urinary bladder cancer tissues

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer

Staging and Grading Last Updated Friday, 14 November 2008

Diagnostic utility of p53 and CK20 immunohistochemical expression grading urothelial malignancies

Is Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer?

The pathology of bladder cancer

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

Immunohistochemical Maspin Expression in Transitional Cell Carcinoma of the Bladder

Influence of stage discrepancy on outcome in. in patients treated with radical cystectomy.

Immunohistochemical Expression Of Cytokeratin 8 And 18 In Breast Carcinoma.

Controversies in the management of Non-muscle invasive bladder cancer

5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.

Case Report Five-Year Survival after Surgery for Invasive Micropapillary Carcinoma of the Stomach

Multiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules

Radical Cystectomy Often Too Late? Yes, But...

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)

Carcinoma of the Renal Pelvis and Ureter Histopathology

Title: Concurrence of villous adenoma and non-muscle invasive bladder cancer arising in the bladder: a case report

Senior of Histopathology Department at Khartoum, Radiation and Isotopes Center

Pathologic Characteristics of Resected Squamous Cell Carcinoma of the Trachea: Prognostic Factors Based on an Analysis of 59 Cases

Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression

Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients

Case Report A Case of p63 Positive Diffuse Large B Cell Lymphoma of the Bladder

Supplementary Information

Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?

Urinary Bladder: WHO Classification and AJCC Staging Update 2017

Hedieh Moradi Tabriz, Golrokh Olfati*, Seyed Ali Ahmadi, Sudabeh Yusefnia

Upper urinary tract urothelial carcinomas (UTUC)

Stromal CD10 immunohistochemical expression in urothelial carcinoma of urinary bladder and correlation with clinicopathological parameters

Key words: undifferentiated carcinoma of the esophagus, immunohistochemical stain, treatment for undifferentiated carcinoma of the esophaqus

Clinical analysis of 29 cases of nasal mucosal malignant melanoma

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer

Value of Uroplakin III in Distinguishing Variants of Primary Bladder Urothelial Carcinoma from Malignancy Metastatic to the Urinary Bladder

Impact of Histopathological Variant on the Outcome of Patients Treated by Radical Cystectomy

Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome

Immunohistochemical Expression of Cytokeratin 5/6 in Gynaecological Tumors.

Peritoneal Involvement in Stage II Colon Cancer

Renal tumors of adults

Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience

Urological Oncology INTRODUCTION. M Hammad Ather, Masooma Zaidi

ROLE OF PROSTATIC BASAL CELL MARKER IN DIAGNOSIS OF PROSTATIC LESIONS

E-Cadherin Expression as a Prognostic Factor in Transitional Cell Carcinoma of the Bladder After Transurethral Resection

Pathologic Assessment of Invasion in TUR Specimens. A. Lopez-Beltran. T1 (ct1)

Analysis of the outcome of young age tongue squamous cell carcinoma

Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital

Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer

A Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis

Microcystic transitional cell carcinoma: a rare tumor of the urinary bladder

High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.

Updates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study

Urology An introduction to cut up DR J R GOEPEL

Synonyms. Nephrogenic metaplasia Mesonephric adenoma

A Review of Outcomes for Stage Ta Bladder Tumors

Urothelial carcinoma is the most common tumor in the

Supporting Information

American Journal of. Medical Case Reports. CAM5.2 Expression in Metastatic Tumours of CNS: A Diagnostic Tool

Neuroendocrine Lung Tumors Myers

Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters

Enrollment Form: Pancreas

When to Integrate Surgery for Metatstatic Urothelial Cancers

3. Guidelines for Reporting Bladder Cancer, Prostate Cancer and Renal Tumours

Invasive Papillary Breast Carcinoma

How Many Diseases in Carcinoma in situ?

International Journal of Health Sciences and Research ISSN:

Case Report Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland

TOPICS FOR DISCUSSION

Spectrum of Lesions in Cystoscopic Bladder Biopsies -A Histopathological Study

Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors

Plasmacytoid Variant Urothelial Carcinoma: Diagnostic and Grossing Challenges. Kailyn Gibson MS, PA-ASCP, Congli Wang, MD

Vascular Endothelial Growth Factor: Correlation with the Different Stages of Papillary Bladder Tumors

Update on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.

Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity

Transcription:

https://doi.org/10.1186/s13104-018-3319-4 BMC Research Notes RESEARCH NOTE Open Access Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis Atif Ali Hashmi 1, Zubaida Fida Hussain 1, Muhammad Irfan 1, Muhammad Muzzammil Edhi 2, Sarah Kanwal 1, Naveen Faridi 1 and Amir Khan 3* Abstract Objectives: Well differentiated keratinized squamous component as a part of urothelial carcinoma can be easily appreciated; however non-keratinizing squamous differentiation closely resembles urothelial differentiation. In addition prognostic significance of CK 5/6 expression in the absence of apparent squamous differentiation is still unclear. Therefore, in the present study we aimed to evaluate the frequency of CK 5/6 expression in 127 cases of urothelial carcinoma and its prognostic significance in loco-regional population. Results: Positive CK5/6 expression was noted in 6.3% (8 cases) and 13.4% (17 cases) revealed focal positive CK 5/6 expression. On the other hand, 80.3% (102 cases) showed negative CK5/6 staining. Significant association of CK5/6 expression was noted with tumor grade and muscularis propria invasion, however no significant association was noted with overall and disease free survival. On the basis of the results of our study we can conclude that CK5/6 is an independent prognostic biomarker in urothelial carcinoma and therefore can be used in the prognostic stratification of the patients with bladder cancer. Keywords: Urothelial carcinoma, Bladder cancer, Cytokeratin 5/6, CK5/6, Deep muscle invasion Introduction Bladder cancer is among one of the most common malignancy in males worldwide and its incidence is even higher in developing countries owing to certain endemic infections [1, 2]. Urothelial carcinoma is the most common histologic subtype of bladder cancer, while Squamous cell carcinoma is seen in association with bladder stones and schistosomiasis. Muscle invasion is one of the most important prognostic factors in bladder cancer; as it necessitates radical therapy and poor 5 year disease free survival [3, 4]. While, well differentiated keratinized squamous component as part of urothelial carcinoma can be easily appreciated; non-keratinizing squamous differentiation closely resembles urothelial differentiation. On the other hand, WHO/ISUP don t recommend *Correspondence: dramirkhan04@gmail.com 3 Kandahar University, Kandahar, Afghanistan Full list of author information is available at the end of the article routine use of immunohistochemical markers to identify squamous differentiation in urothelial carcinoma. Conversely, markers of squamous differentiation like p63, p40, CK5/6 can be positive in urothelial carcinoma [5]. In addition prognostic significance of CK 5/6 expression in the absence of apparent squamous differentiation is still unclear. Therefore, in the present study we aimed to evaluate the frequency of CK 5/6 expression in urothelial carcinoma and its prognostic significance in loco-regional population. Main text Total 240 diagnosed cases of urothelial carcinoma specimens were selected from records of pathology department. All patients underwent surgeries at Liaquat National hospital, Karachi from January 2010 till December 2014 over a period of 5 years. The study was approved by research and ethical review committee of Liaquat National Hospital and informed written consent The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creat iveco mmons.org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons.org/ publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Page 2 of 5 was taken from all patients at the time of surgery. Hematoxylin and eosin stained slides and paraffin blocks of all cases were retrieved and new sections were cut when necessary. Slides of all cases were reviewed by two senior histopathologists and pathologic characteristics like histologic type, tumor grade, lamina propria invasion, muscularis propria invasion were evaluated. Clinical records of 61 patients were available and are thus reviewed from institutional records to evaluate history of radiation and chemotherapy and recurrence status. Moreover, representative tissue blocks of 127 cases were available for CK5/6 immunohistochemistry. CK5/6 IHC was performed by using FLEX Monoclonal Mouse Anti-human Cytokeratin 5/6, clone D5/16 B4 (Lot No. 20042129) by DAKO envision method according to manufacturers protocol on 127 cases of urothelial carcinoma (on representative tissue blocks). Results of IHC staining were interpreted by two senior histopathologists with more than 5 years experience of reporting histopathology and immunohistochemistry and they were blinded by other histopathological features of the tumors. For quantification, at least 1000 cells were counted in 10 HPFs (40 ). Intermediate to strong cytoplasmic and membranous staining in more than 10% of tumor cells was considered positive. Weak to intermediate staining in < 10% was taken as focal positive, while no staining was considered as negative (Fig. 1). Recurrence status and follow-up were evaluated by reviewing hospital medical records. Overall survival was taken as time from surgical excision till death or last follow-up and disease free survival was defined as time between surgical excision and local recurrence or distant metastasis, death or last follow-up. All cases of primary urothelial carcinoma were included in the study. Cases of squamous cell carcinoma or those cases of urothelial carcinoma showing divergent differentiation (including squamous differentiation) were excluded from the study. Statistical package for social sciences (SPSS 21) was used for data compilation and analysis. Mean and standard deviation were calculated for quantitative variables. Frequency and percentage were calculated for qualitative variables. Chi square was applied to determine association. Student t test or Mann Witney test were applied to compare difference in means among groups. Survival curves were plotted using Kaplan Meier method and the significance of difference between survival curves were determined using log-rank ratio. P value 0.05 was taken as significant. Mean age of patients was 63.23 + 13.9 years with male to female ratio of 3:1. 95.8% specimens were of transurethral resections. 50.8% (122 cases) were of high grade morphology, whereas 49.2% (118 cases) showed Fig. 1 CK5/6 expression in bladder carcinoma

Page 3 of 5 low grade histology. Lamina propria invasion was seen in 30.4% (73 cases), while muscularis propria invasion was noted in 22.9% (55 cases). Mean follow up of patients involved in the study was 22.0 + 13.74 months and recurrence was seen in 45.9% (28 cases) as presented in Table 1. Positive CK5/6 expression was noted in 6.3% (8 cases) and 13.4% (17 cases) revealed focal positive CK 5/6 expression. On the other hand, 80.3% (102 cases) showed negative CK5/6 staining. Significant association of CK5/6 expression was noted with tumor grade and muscularis propria invasion, however no significant association was noted with lamina propria Table 1 Clinicopathologic features of bladder carcinoma n (%) Age (years) a 63.28 ± 13.90 Follow up (months) a 22.00 ± 13.74 Gender Male 182 (75.8) Female 58 (24.2) Tissue type Transurethral resection 230 (95.8) Radical cystectomy 10 (4.2) Tumor grade Low grade papillary urothelial carcinoma 118 (49.2) High grade papillary urothelial carcinoma 122 (50.8) Lamina propria invasion Present 73 (30.4) Absent 167 (69.6) Deep muscle invasion Present 55 (22.9) Absent 140 (58.3) Can t assessed 45 (18.8) Recurrence (n = 61) Yes 28 (45.9) No 33 (54.1) Survival status (n = 61) Alive 52 (85.2) Expired 9 (14.8) invasion and disease free survival (Table 2 and Figs. 2 and 3). In the present study we found that CK5/6 expression is low in urothelial carcinoma in our set up; however, its positivity signifies adverse prognostic features like higher tumor grade and muscularis propria invasion. CK5/6 is a basal cytokeratin which normally expresses in squamous epithelium and in squamous cell carcinoma. Although diagnosis of squamous cell carcinoma in bladder is restricted to those tumors which show pure squamous differentiation in the absence of any urothelial component. Conversely, advanced urothelial carcinoma can show divergent differentiation (including squamous component) in up to 50% of cases and is associated with poor disease progression [6]. Morphologic diagnosis of squamous differentiation in urothelial carcinoma is based on the presence of either intercellular bridges or presence of keratinization in the form of keratin pearls or individual cell keratinization; however non-keratinizing or poorly differentiated squamous component can closely resemble urothelial carcinoma and therefore can t be readily apparent. Gaisa et al. [7] performed IHC markers of squamous differentiation including CK5/6 and CK4/14; and found squamous differentiation in a high proportion of urothelial carcinoma without morphologic evidence of squamous differentiation. Langer et al. evaluated the prognostic value of keratin subtyping in urothelial carcinoma and revealed the prognostic impact of various cytokeratin staining in urothelial carcinoma including CK5/6. Limitations One of the major limitations of our study was that we performed only single biomarker of squamous differentiation in our study; use of multiple markers like CK5/14 and CK4/14 could increase the sensitivity of the study. However, on the basis of the results of our study we can conclude that CK5/6 is an independent prognostic biomarker in urothelial carcinoma and therefore can be used in the prognostic stratification of the patients with bladder cancer. a Mean ± SD

Page 4 of 5 Table 2 Association of CK 5/6 expression with clinicopathologic features of bladder cancer CK 5/6 n (%) P value Positive Negative Focal positive Total Gender Male 8 (100) 77 (75.5) 8 (47.1) 93 (73.2) 0.014 Female 0 (0) 25 (24.5) 9 (52.9) 34 (26.8) Age group 25 years 0 (0) 1 (1) 0 (0) 1 (0.8) 0.613 26 50 years 2 (25) 26 (25.5) 2 (11.8) 30 (23.6) > 50 years 6 (75) 75 (73.5) 15 (88.2) 96 (75.6) Tissue type Transurethral resection 6 (75) 99 (97.1) 17 (100) 122 (96.1) 0.049 Radical cystectomy 2 (25) 3 (2.9) 0 (0) 5 (3.9) Tumor grade Low grade 0 (0) 59 (57.8) 5 (29.4) 64 (50.4) 0.000 High grade 8 (100) 43 (42.2) 12 (70.6) 63 (49.6) Lamina propria invasion Present 5 (62.5) 31 (30.4) 3 (17.6) 39 (30.7) 0.081 Absent 3 (37.5) 71 (69.6) 14 (82.4) 88 (69.3) Deep muscle invasion Present 5 (62.5) 19 (18.6) 2 (11.8) 26 (20.5) 0.049 Absent 1 (12.5) 47 (46.1) 10 (58.8) 58 (45.7) Can t assessed 2 (25) 36 (35.3) 5 (29.4) 43 (33.9) Recurrence (n = 54) Yes 2 (50) 18 (40) 2 (40) 22 (40.7) 1.000 No 2 (50) 27 (60) 3 (60) 32 (59.3) Total 4 45 5 54 Survival status (n = 54) Alive 3 (75) 39 (86.7) 5 (100) 47 (87) 0.514 Expired 1 (25) 6 (13.3) 0 (0) 7 (13) Total 4 45 5 54 Fisher exact test applied P 0.05, considered as significant

Page 5 of 5 Abbreviations IHC: immunohistochemistry; WHO: World Health Organization; ISUP: International Society of Urological Pathology. Authors contributions AAH and ZFH: main author of manuscript, have made substantial contributions to conception and design of study. MI, MME and SK: have been involved in requisition of data. NF AND AK have been involved in analysis of the data and revision of the manuscript. All authors revise the manuscript. All authors read and approved the final manuscript. Author details 1 Liaquat National Hospital and Medical College, Karachi, Pakistan. 2 Brown University, Providence, RI, USA. 3 Kandahar University, Kandahar, Afghanistan. Acknowledgements We gratefully acknowledge all staff members of Pathology, Liaquat National Hospital, Karachi, Pakistan for their help and cooperation. Competing interests The authors declare that they have no competing interests. Availability of data and materials Please contact author, Atif Ali Hashmi (doc_atif2005@yahoo.com) for data requests. Fig. 2 Kalpien Meier for CK5/6 overexpression in bladder cancer for overall survival Consent to publish Not applicable. Ethical approval and consent to participate Ethics committee of Liaquat National Hospital, Karachi, Pakistan approved the study. Written informed consent was obtained from the patients for the participation. Funding There was no funding available for this manuscript. Publisher s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Received: 26 January 2018 Accepted: 23 March 2018 Fig. 3 Kalpien Meier for CK5/6 overexpression in bladder cancer for recurrence References 1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002 cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No 5, version 2.0. IARC, Lyon; 2004. 2. Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol. 2008;42(Suppl 218):12 20. 3. Pearse HD, Reed RR, Hodges CV. Radical cystectomy for bladder cancer. J Urol. 1978;119:216 8. 4. Skinner DG, Lieskovsky G. Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in the management of invasive bladder cancer. J Urol. 1984;131:1069 72. 5. Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 2001;116(6):823 30. 6. Langner C, Wegscheider BJ, Rehak P, Ratschek M, Zigeuner R. Prognostic value of keratin subtyping in transitional cell carcinoma of the upper urinary tract. Virchows Arch. 2004;445(5):442 8. 7. Gaisa NT, Braunschweig T, Reimer N, Bornemann J, Eltze E, Siegert S, Toma M, Villa L, Hartmann A, Knuechel R. Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer. Virchows Arch. 2011;458(3):301 12.